Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
Insulin glulisine
Insulin aspart
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- patients with type 2 diabetes for at least one year
- treated with oral antidiabetic agents (OADs) for at least 6 months
- Baseline C-peptide ≥0.1 nmol/L
- BMI (body mass index) between 30 and 40 kg/m2
- HbA1c (glycosylated hemoglobin) < 8.5%
- signed informed consent
Exclusion Criteria:
- type I diabetes mellitus
- current treatment with insulin
- pregnant and breast-feeding women
- any medication known to influence insulin sensitivity
- current treatment with systemic corticosteroids
- history of acute metabolic complications in the past 3 months
- recurrent severe hypoglycaemia or hypoglycaemic unawareness
- active proliferative diabetic retinopathy and known diabetic gastroparesis
- impaired hepatic function, as shown but not limited to ALT or AST above 2 times the upper limit of normal
- clinically relevant illness such as nephropathy and impaired renal function as shown by clearance < 30 ml/min
- any history or presence of clinically relevant abnormality, medical condition (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, ocular or infectious disease; any acute infectious disease or signs of acute illness making implementation of the protocol or interpretation of the results difficult
- hypersensitivity to insulins or insulin analogs
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Sanofi-Aventis Administrative Office
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
insulin glulisine + insulin aspart
insulin aspart + insulin glulisine
Arm Description
insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
Outcomes
Primary Outcome Measures
Area under the plasma glucose concentration curve (AUC) between 0 and 1 hour after insulin injection AUC(0-1h)
Secondary Outcome Measures
Area under the curve of plasma glucose concentration AUC(0-2h)
Area under the curve of plasma glucose concentration AUC(0-4h)
Area under the curve of plasma glucose concentration AUC(0-6h)
Delta plasma glucose at 1h after standard meal
Maximum glucose concentration (GLU max)
Maximum glucose excursion (delta GLU max)
Time to delta GLU max
Time to fraction of total glucose AUC(10%, 20%)
Area under the plasma insulin concentration curve AUC (0-1h)
Area under the plasma insulin concentration curve AUC (0-2h)
Area under the plasma insulin concentration curve AUC (0-4h)
Area under the plasma insulin concentration curve AUC (0-6h)
Maximum insulin concentration (Cmax)
Time to fraction of total insulin AUC (10%, 20%)
Time to Cmax
Hypoglycaemia and adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01159353
Brief Title
Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart
Official Title
A Randomized, Double Blind Study to Assess the Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart
Study Type
Interventional
2. Study Status
Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Sanofi
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Primary Objective:
To assess the effect of insulin glulisine on the post-prandial plasma glucose excursion during the first hour after a standard meal in comparison to insulin aspart in obese subjects with type 2 diabetes.
Secondary Objectives:
Pharmacodynamic objectives:
To assess the effect of insulin glulisine on the postprandial plasma glucose excursion during 6 hours after a standard meal in comparison to insulin aspart.
Pharmacokinetic objective:
To assess post-prandial plasma insulin excursion after a standard meal, in each treatment groups
Safety objective:
To assess the safety of insulin glulisine in comparison to insulin aspart
Detailed Description
Duration of treatment: two study days separated by a 7-day wash-out period
Duration of observation:
screening period of 1-2 weeks, >2 study days (with a wash-out period of 7 days between the study days),
Follow-up visit (within 2 weeks after the end of the study treatment period).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
37 (Actual)
8. Arms, Groups, and Interventions
Arm Title
insulin glulisine + insulin aspart
Arm Type
Experimental
Arm Description
insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
Arm Title
insulin aspart + insulin glulisine
Arm Type
Experimental
Arm Description
insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
Intervention Type
Drug
Intervention Name(s)
Insulin glulisine
Other Intervention Name(s)
Apidra
Intervention Description
Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
Intervention Type
Drug
Intervention Name(s)
Insulin aspart
Other Intervention Name(s)
NovoRapid
Intervention Description
Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
Primary Outcome Measure Information:
Title
Area under the plasma glucose concentration curve (AUC) between 0 and 1 hour after insulin injection AUC(0-1h)
Time Frame
At day 1 of each treatment period
Secondary Outcome Measure Information:
Title
Area under the curve of plasma glucose concentration AUC(0-2h)
Time Frame
At day 1 of each treatment period
Title
Area under the curve of plasma glucose concentration AUC(0-4h)
Time Frame
At day 1 of each treatment period
Title
Area under the curve of plasma glucose concentration AUC(0-6h)
Time Frame
At day 1 of each treatment period
Title
Delta plasma glucose at 1h after standard meal
Time Frame
At day 1 of each treatment period
Title
Maximum glucose concentration (GLU max)
Time Frame
At day 1 of each treatment period
Title
Maximum glucose excursion (delta GLU max)
Time Frame
At day 1 of each treatment period
Title
Time to delta GLU max
Time Frame
At day 1 of each treatment period
Title
Time to fraction of total glucose AUC(10%, 20%)
Time Frame
At day 1 of each treatment period
Title
Area under the plasma insulin concentration curve AUC (0-1h)
Time Frame
At day 1 of each treatment period
Title
Area under the plasma insulin concentration curve AUC (0-2h)
Time Frame
At day 1 of each treatment period
Title
Area under the plasma insulin concentration curve AUC (0-4h)
Time Frame
At day 1 of each treatment period
Title
Area under the plasma insulin concentration curve AUC (0-6h)
Time Frame
At day 1 of each treatment period
Title
Maximum insulin concentration (Cmax)
Time Frame
At day 1 of each treatment period
Title
Time to fraction of total insulin AUC (10%, 20%)
Time Frame
At day 1 of each treatment period
Title
Time to Cmax
Time Frame
At day 1 of each treatment period
Title
Hypoglycaemia and adverse events
Time Frame
from randomization to the end of study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with type 2 diabetes for at least one year
treated with oral antidiabetic agents (OADs) for at least 6 months
Baseline C-peptide ≥0.1 nmol/L
BMI (body mass index) between 30 and 40 kg/m2
HbA1c (glycosylated hemoglobin) < 8.5%
signed informed consent
Exclusion Criteria:
type I diabetes mellitus
current treatment with insulin
pregnant and breast-feeding women
any medication known to influence insulin sensitivity
current treatment with systemic corticosteroids
history of acute metabolic complications in the past 3 months
recurrent severe hypoglycaemia or hypoglycaemic unawareness
active proliferative diabetic retinopathy and known diabetic gastroparesis
impaired hepatic function, as shown but not limited to ALT or AST above 2 times the upper limit of normal
clinically relevant illness such as nephropathy and impaired renal function as shown by clearance < 30 ml/min
any history or presence of clinically relevant abnormality, medical condition (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, ocular or infectious disease; any acute infectious disease or signs of acute illness making implementation of the protocol or interpretation of the results difficult
hypersensitivity to insulins or insulin analogs
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Facility Information:
Facility Name
Sanofi-Aventis Administrative Office
City
Paris
Country
France
12. IPD Sharing Statement
Learn more about this trial
Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart
We'll reach out to this number within 24 hrs